Cargando…
Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study
BACKGROUND: Preventative medication reduces hospitalisations in people with cystic fibrosis (PWCF) but adherence is poor. We assessed the feasibility of a randomised controlled trial of a complex intervention, which combines display of real time adherence data and behaviour change techniques. METHOD...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458785/ https://www.ncbi.nlm.nih.gov/pubmed/30975206 http://dx.doi.org/10.1186/s12890-019-0834-6 |
_version_ | 1783410082566897664 |
---|---|
author | Hind, Daniel Drabble, Sarah J. Arden, Madelynne A. Mandefield, Laura Waterhouse, Simon Maguire, Chin Cantrill, Hannah Robinson, Louisa Beever, Daniel Scott, Alexander J. Keating, Sam Hutchings, Marlene Bradley, Judy Nightingale, Julia Allenby, Mark I. Dewar, Jane Whelan, Pauline Ainsworth, John Walters, Stephen J. O’Cathain, Alicia Wildman, Martin J. |
author_facet | Hind, Daniel Drabble, Sarah J. Arden, Madelynne A. Mandefield, Laura Waterhouse, Simon Maguire, Chin Cantrill, Hannah Robinson, Louisa Beever, Daniel Scott, Alexander J. Keating, Sam Hutchings, Marlene Bradley, Judy Nightingale, Julia Allenby, Mark I. Dewar, Jane Whelan, Pauline Ainsworth, John Walters, Stephen J. O’Cathain, Alicia Wildman, Martin J. |
author_sort | Hind, Daniel |
collection | PubMed |
description | BACKGROUND: Preventative medication reduces hospitalisations in people with cystic fibrosis (PWCF) but adherence is poor. We assessed the feasibility of a randomised controlled trial of a complex intervention, which combines display of real time adherence data and behaviour change techniques. METHODS: Design: Pilot, open-label, parallel-group RCT with concurrent semi-structured interviews. Participants: PWCF at two Cystic Fibrosis (CF) units. Eligible: aged 16 or older; on the CF registry. Ineligible: post-lung transplant or on the active list; unable to consent; using dry powder inhalers. Interventions: Central randomisation on a 1:1 allocation to: (1) intervention, linking nebuliser use with data recording and transfer capability to a software platform, and behavioural strategies to support self-management delivered by trained interventionists (n = 32); or, (2) control, typically face-to-face meetings every 3 months with CF team (n = 32). Outcomes: RCT feasibility defined as: recruitment of ≥ 48 participants (75% of target) in four months (pilot primary outcome); valid exacerbation data available for ≥ 85% of those randomised (future RCT primary outcome); change in % medication adherence; FEV(1) percent predicted (key secondaries in future RCT); and perceptions of trial procedures, in semi-structured interviews with intervention (n = 14) and control (n = 5) participants, interventionists (n = 3) and CF team members (n = 5). RESULTS: The pilot trial recruited to target, randomising 33 to intervention and 31 to control in the four-month period, June–September 2016. At study completion (30th April 2017), 60 (94%; Intervention = 32, Control =28) participants contributed good quality exacerbation data (intervention: 35 exacerbations; control: 25 exacerbation). The mean change in adherence and baseline-adjusted FEV(1) percent predicted were higher in the intervention arm by 10% (95% CI: -5.2 to 25.2) and 5% (95% CI -2 to 12%) respectively. Five serious adverse events occurred, none related to the intervention. The mean change in adherence was 10% (95% CI: -5.2 to 25.2), greater in the intervention arm. Interventionists delivered insufficient numbers of review sessions due to concentration on participant recruitment. This left interventionists insufficient time for key intervention procedures. A total of 10 key changes that were made to RCT procedures are summarised. CONCLUSIONS: With improved research processes and lower monthly participant recruitment targets, a full-scale trial is feasible. TRIAL REGISTRATION: ISRCTN13076797. Prospectively registered on 07/06/2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12890-019-0834-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6458785 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64587852019-04-22 Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study Hind, Daniel Drabble, Sarah J. Arden, Madelynne A. Mandefield, Laura Waterhouse, Simon Maguire, Chin Cantrill, Hannah Robinson, Louisa Beever, Daniel Scott, Alexander J. Keating, Sam Hutchings, Marlene Bradley, Judy Nightingale, Julia Allenby, Mark I. Dewar, Jane Whelan, Pauline Ainsworth, John Walters, Stephen J. O’Cathain, Alicia Wildman, Martin J. BMC Pulm Med Research Article BACKGROUND: Preventative medication reduces hospitalisations in people with cystic fibrosis (PWCF) but adherence is poor. We assessed the feasibility of a randomised controlled trial of a complex intervention, which combines display of real time adherence data and behaviour change techniques. METHODS: Design: Pilot, open-label, parallel-group RCT with concurrent semi-structured interviews. Participants: PWCF at two Cystic Fibrosis (CF) units. Eligible: aged 16 or older; on the CF registry. Ineligible: post-lung transplant or on the active list; unable to consent; using dry powder inhalers. Interventions: Central randomisation on a 1:1 allocation to: (1) intervention, linking nebuliser use with data recording and transfer capability to a software platform, and behavioural strategies to support self-management delivered by trained interventionists (n = 32); or, (2) control, typically face-to-face meetings every 3 months with CF team (n = 32). Outcomes: RCT feasibility defined as: recruitment of ≥ 48 participants (75% of target) in four months (pilot primary outcome); valid exacerbation data available for ≥ 85% of those randomised (future RCT primary outcome); change in % medication adherence; FEV(1) percent predicted (key secondaries in future RCT); and perceptions of trial procedures, in semi-structured interviews with intervention (n = 14) and control (n = 5) participants, interventionists (n = 3) and CF team members (n = 5). RESULTS: The pilot trial recruited to target, randomising 33 to intervention and 31 to control in the four-month period, June–September 2016. At study completion (30th April 2017), 60 (94%; Intervention = 32, Control =28) participants contributed good quality exacerbation data (intervention: 35 exacerbations; control: 25 exacerbation). The mean change in adherence and baseline-adjusted FEV(1) percent predicted were higher in the intervention arm by 10% (95% CI: -5.2 to 25.2) and 5% (95% CI -2 to 12%) respectively. Five serious adverse events occurred, none related to the intervention. The mean change in adherence was 10% (95% CI: -5.2 to 25.2), greater in the intervention arm. Interventionists delivered insufficient numbers of review sessions due to concentration on participant recruitment. This left interventionists insufficient time for key intervention procedures. A total of 10 key changes that were made to RCT procedures are summarised. CONCLUSIONS: With improved research processes and lower monthly participant recruitment targets, a full-scale trial is feasible. TRIAL REGISTRATION: ISRCTN13076797. Prospectively registered on 07/06/2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12890-019-0834-6) contains supplementary material, which is available to authorized users. BioMed Central 2019-04-11 /pmc/articles/PMC6458785/ /pubmed/30975206 http://dx.doi.org/10.1186/s12890-019-0834-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Hind, Daniel Drabble, Sarah J. Arden, Madelynne A. Mandefield, Laura Waterhouse, Simon Maguire, Chin Cantrill, Hannah Robinson, Louisa Beever, Daniel Scott, Alexander J. Keating, Sam Hutchings, Marlene Bradley, Judy Nightingale, Julia Allenby, Mark I. Dewar, Jane Whelan, Pauline Ainsworth, John Walters, Stephen J. O’Cathain, Alicia Wildman, Martin J. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study |
title | Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study |
title_full | Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study |
title_fullStr | Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study |
title_full_unstemmed | Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study |
title_short | Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study |
title_sort | supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458785/ https://www.ncbi.nlm.nih.gov/pubmed/30975206 http://dx.doi.org/10.1186/s12890-019-0834-6 |
work_keys_str_mv | AT hinddaniel supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT drabblesarahj supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT ardenmadelynnea supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT mandefieldlaura supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT waterhousesimon supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT maguirechin supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT cantrillhannah supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT robinsonlouisa supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT beeverdaniel supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT scottalexanderj supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT keatingsam supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT hutchingsmarlene supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT bradleyjudy supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT nightingalejulia supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT allenbymarki supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT dewarjane supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT whelanpauline supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT ainsworthjohn supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT waltersstephenj supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT ocathainalicia supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy AT wildmanmartinj supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy |